11 terminated, 2 active not recruiting, 2 completed, 2 withdrawn. 11 Phase 2, 10 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Terminated 8, Active not recruiting 2, Withdrawn 1 |
| Phase 1 | 10 | Terminated 5, Completed 2, Withdrawn 2, Active not recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow sabatolimab: new trials by email Literature Review of sabatolimab trials Research Report on sabatolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial MBG-453 + Azacitidine - AML | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-12-30 | 2026-07-08 |
| A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2024-12-20 | 2024-04-11 | |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. decitabine, spartalizumab, sabatolimab - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 33 | 2023-02-28 | 2026-09-22 |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS MBG453, Azacitidine, Decitabine - Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Novartis Pharmaceuticals | 39 | 2022-03-17 | 2025-10-16 |
| MBG453 in Lower Risk MDS MBG453 - Myelodysplastic Syndromes | Phase 2 | Terminated | Massachusetts General Hospital | 10 | 2022-01-27 | 2026-10-20 |
| Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. Sabatolimab, Azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 24 | 2021-09-14 | 2025-10-16 |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS MBG453, NIS793, canakinumab - Myelodysplastic Syndromes | Phase 1 | Terminated | Novartis Pharmaceuticals | 33 | 2021-06-18 | 2025-10-10 |
| A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants sabatolimab, azacitidine, venetoclax - Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Novartis Pharmaceuticals | 20 | 2021-05-31 | 2025-10-09 |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy MBG453, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 90 | 2020-09-01 | 2026-01-13 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Sabatolimab, Azacitidine, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 530 | 2020-06-08 | 2026-01-13 |
| Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM MBG453 - Glioblastoma Multiforme | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2020-02-18 | 2026-10-07 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2019-09-26 | 2025-08-07 |
| HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) HDM201, MBG453, Venetoclax - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) | Phase 1 | Terminated | Novartis Pharmaceuticals | 52 | 2019-06-24 | 2025-10-10 |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). MBG453, Placebo, Hypomethylating agents - Myelodysplastic Syndromes | Phase 2 | Terminated | Novartis Pharmaceuticals | 127 | 2019-06-04 | 2026-01-13 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Decitabine, PDR001, MBG453 - Leukemia, Leukemia, Myeloid | Phase 1 | Completed | Novartis Pharmaceuticals | 241 | 2017-07-06 | 2025-05-18 |
| Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies MBG453, PDR001, Decitabine - Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 252 | 2015-11-23 | 2023-12-06 |
Myelodysplastic Syndromes (9) · Leukemia, Myeloid, Acute (5) · Leukemia, Myelomonocytic, Chronic (3) · Primary Myelofibrosis (2) · Bone Marrow Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Melanoma (1) · Myeloproliferative Disorders (1) · Neoplasm, Residual (1) · Polycythemia Vera (1)
Novartis Pharmaceuticals (14) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (12) · Italy (10) · Spain (10) · Germany (9) · Australia (7) · France (7) · Canada (6) · Japan (5) · South Korea (5) · Greece (4) · Netherlands (4) · Singapore (4) · Switzerland (4) · Taiwan (4) · Turkey (Türkiye) (4)
Andrew Brunner, MD (1) · Courtney DiNardo, MD (1) · Lawrence Kleinberg, MD (1)
PMID 33883177, PMID 37083373, PMID 38065203, PMID 39209782, PMID 40334082
2019 (5), 2018 (2), 2015 (1), 2016 (1)